Literature DB >> 22323753

SMN1 gene duplications are associated with sporadic ALS.

H M Blauw1, C P Barnes, P W J van Vught, W van Rheenen, M Verheul, E Cuppen, J H Veldink, L H van den Berg.   

Abstract

OBJECTIVE: To investigate the role of SMN1 and SMN2 copy number variation and point mutations in amyotrophic lateral sclerosis (ALS) pathogenesis in a large population.
METHODS: We conducted a genetic association study including 847 patients with ALS and 984 controls. We used multiplexed ligation-dependent probe amplification (MLPA) assays to determine SMN1 and SMN2 copy numbers and examined effects on disease susceptibility and disease course. Furthermore, we sequenced SMN genes to determine if SMN mutations were more prevalent in patients with ALS. A meta-analysis was performed with results from previous studies.
RESULTS: SMN1 duplications were associated with ALS susceptibility (odds ratio [OR] 2.07, 95% confidence interval [CI] 1.34-3.20, p = 0.001). A meta-analysis with previous data including 3,469 individuals showed a similar effect: OR 1.85, 95% CI 1.18-2.90, p = 0.008). SMN1 deletions and SMN2 copy number status were not associated with ALS. SMN1 or SMN2 copy number variants had no effect on survival or the age at onset of the disease. We found no enrichment of SMN point mutations in patients with ALS.
CONCLUSIONS: Our data provide firm evidence for a role of common SMN1 duplications in ALS, and raise new questions regarding the disease mechanisms involved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22323753      PMCID: PMC3304946          DOI: 10.1212/WNL.0b013e318249f697

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  16 in total

1.  Molecular diagnosis of non-deletion SMA patients using quantitative PCR of SMN exon 7.

Authors:  C F Rochette; L C Surh; P N Ray; P E McAndrew; T W Prior; A H Burghes; M Vanasse; L R Simard
Journal:  Neurogenetics       Date:  1997-09       Impact factor: 2.660

2.  Homozygous deletion of the survival motor neuron 2 gene is a prognostic factor in sporadic ALS.

Authors:  J H Veldink; L H van den Berg; J M Cobben; R P Stulp; J M De Jong; O J Vogels; F Baas; J H Wokke; H Scheffer
Journal:  Neurology       Date:  2001-03-27       Impact factor: 9.910

3.  Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification.

Authors:  Jan P Schouten; Cathal J McElgunn; Raymond Waaijer; Danny Zwijnenburg; Filip Diepvens; Gerard Pals
Journal:  Nucleic Acids Res       Date:  2002-06-15       Impact factor: 16.971

4.  Differential SMN2 expression associated with SMA severity.

Authors:  D K Gavrilov; X Shi; K Das; T C Gilliam; C H Wang
Journal:  Nat Genet       Date:  1998-11       Impact factor: 38.330

5.  PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing.

Authors:  D A Nickerson; V O Tobe; S L Taylor
Journal:  Nucleic Acids Res       Date:  1997-07-15       Impact factor: 16.971

6.  SMN1 gene, but not SMN2, is a risk factor for sporadic ALS.

Authors:  P Corcia; W Camu; J-M Halimi; P Vourc'h; C Antar; S Vedrine; B Giraudeau; B de Toffol; C R Andres
Journal:  Neurology       Date:  2006-08-23       Impact factor: 9.910

7.  SMN genotypes producing less SMN protein increase susceptibility to and severity of sporadic ALS.

Authors:  J H Veldink; S Kalmijn; A H Van der Hout; H H Lemmink; G J Groeneveld; C Lummen; H Scheffer; J H J Wokke; L H Van den Berg
Journal:  Neurology       Date:  2005-08-10       Impact factor: 9.910

8.  El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors.

Authors:  B R Brooks
Journal:  J Neurol Sci       Date:  1994-07       Impact factor: 3.181

9.  Abnormal SMN1 gene copy number is a susceptibility factor for amyotrophic lateral sclerosis.

Authors:  Philippe Corcia; Véronique Mayeux-Portas; Jawad Khoris; Bertrand de Toffol; Alain Autret; Jean-Pierre Müh; William Camu; Christian Andres
Journal:  Ann Neurol       Date:  2002-02       Impact factor: 10.422

10.  Relative impact of nucleotide and copy number variation on gene expression phenotypes.

Authors:  Barbara E Stranger; Matthew S Forrest; Mark Dunning; Catherine E Ingle; Claude Beazley; Natalie Thorne; Richard Redon; Christine P Bird; Anna de Grassi; Charles Lee; Chris Tyler-Smith; Nigel Carter; Stephen W Scherer; Simon Tavaré; Panagiotis Deloukas; Matthew E Hurles; Emmanouil T Dermitzakis
Journal:  Science       Date:  2007-02-09       Impact factor: 47.728

View more
  26 in total

1.  Single-Cell Analysis of SMN Reveals Its Broader Role in Neuromuscular Disease.

Authors:  Natalia Rodriguez-Muela; Nadia K Litterman; Erika M Norabuena; Jesse L Mull; Maria José Galazo; Chicheng Sun; Shi-Yan Ng; Nina R Makhortova; Andrew White; Maureen M Lynes; Wendy K Chung; Lance S Davidow; Jeffrey D Macklis; Lee L Rubin
Journal:  Cell Rep       Date:  2017-02-07       Impact factor: 9.423

Review 2.  Genetics of Amyotrophic Lateral Sclerosis.

Authors:  Mehdi Ghasemi; Robert H Brown
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

Review 3.  Genetic causes of amyotrophic lateral sclerosis: new genetic analysis methodologies entailing new opportunities and challenges.

Authors:  Giuseppe Marangi; Bryan J Traynor
Journal:  Brain Res       Date:  2014-10-12       Impact factor: 3.252

4.  Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers.

Authors:  Marka van Blitterswijk; Bianca Mullen; Michael G Heckman; Matthew C Baker; Mariely DeJesus-Hernandez; Patricia H Brown; Melissa E Murray; Ging-Yuek R Hsiung; Heather Stewart; Anna M Karydas; Elizabeth Finger; Andrew Kertesz; Eileen H Bigio; Sandra Weintraub; Marsel Mesulam; Kimmo J Hatanpaa; Charles L White; Manuela Neumann; Michael J Strong; Thomas G Beach; Zbigniew K Wszolek; Carol Lippa; Richard Caselli; Leonard Petrucelli; Keith A Josephs; Joseph E Parisi; David S Knopman; Ronald C Petersen; Ian R Mackenzie; William W Seeley; Lea T Grinberg; Bruce L Miller; Kevin B Boylan; Neill R Graff-Radford; Bradley F Boeve; Dennis W Dickson; Rosa Rademakers
Journal:  Neurobiol Aging       Date:  2014-05-02       Impact factor: 4.673

Review 5.  Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis.

Authors:  Emanuele D'Amico; Pam Factor-Litvak; Regina M Santella; Hiroshi Mitsumoto
Journal:  Free Radic Biol Med       Date:  2013-06-21       Impact factor: 7.376

Review 6.  Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder.

Authors:  Chi-Tso Chiu; Zhifei Wang; Joshua G Hunsberger; De-Maw Chuang
Journal:  Pharmacol Rev       Date:  2013-01-08       Impact factor: 25.468

7.  Mutant superoxide dismutase 1 (SOD1), a cause of amyotrophic lateral sclerosis, disrupts the recruitment of SMN, the spinal muscular atrophy protein to nuclear Cajal bodies.

Authors:  Shingo Kariya; Diane B Re; Arnaud Jacquier; Katelyn Nelson; Serge Przedborski; Umrao R Monani
Journal:  Hum Mol Genet       Date:  2012-05-11       Impact factor: 6.150

8.  The neuroprotective drug riluzole acts via small conductance Ca2+-activated K+ channels to ameliorate defects in spinal muscular atrophy models.

Authors:  Maria Dimitriadi; Min Jeong Kye; Geetika Kalloo; Jill M Yersak; Mustafa Sahin; Anne C Hart
Journal:  J Neurosci       Date:  2013-04-10       Impact factor: 6.167

9.  SMN1 Duplications Are Associated With Progressive Muscular Atrophy, but Not With Multifocal Motor Neuropathy and Primary Lateral Sclerosis.

Authors:  Jeroen W Bos; Ewout J N Groen; Renske I Wadman; Chantall A D Curial; Naomi N Molleman; Marinka Zegers; Paul W J van Vught; Reinier Snetselaar; Raymon Vijzelaar; W Ludo van der Pol; Leonard H van den Berg
Journal:  Neurol Genet       Date:  2021-06-22

10.  Spliceosome integrity is defective in the motor neuron diseases ALS and SMA.

Authors:  Hitomi Tsuiji; Yohei Iguchi; Asako Furuya; Ayane Kataoka; Hiroyuki Hatsuta; Naoki Atsuta; Fumiaki Tanaka; Yoshio Hashizume; Hiroyasu Akatsu; Shigeo Murayama; Gen Sobue; Koji Yamanaka
Journal:  EMBO Mol Med       Date:  2013-01-25       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.